Alectinib has been reported to be effective for crizotinib‐resistant ALK mutation, including L1196M gatekeeper mutation, and shows objective responses in crizotinib‐resistant ALK‐rearranged non‐small cell lung cancers (NSCLCs)[4, 9]. The gene discussed is ALK; the disease is lung cancer.